The handheld catheterization device AI-GUIDE, created by Lincoln Laboratory and Massachusetts General Hospital, promises improved health outcomes for injured service members and civilians.
LifeTech Scientific, a Shenzhen, China-based developer of advanced minimally invasive medical devices for cardiovascular diseases and disorders, has received CE MDR certification for its self-developed Yuranos abdominal aortic stent graft system, which is indicated for endovascular repair of infrarenal abdominal aortic aneurysms and can be used in combination with the company’s G-iliac iliac bifurcation stent system and SilverFlow iliac artery covered stent system
The grant will assist Senphonix and the University of Arizona in their efforts to strengthen the device’s wireless components.
With the FDA designate in hand, XCath will further the development of its system that is intended to broaden access to stroke treatment globally.
Breakthrough designation for Nutromics’ namesake patch applies to the wearable platform’s function in vancomycin drug monitoring.
Pelvic organ prolapse is a common but often overlooked condition that affects millions of women. It occurs when the tissues that support the pelvic organs weaken, allowing organs such as the bladder, uterus or rectum to shift from their normal position. Doctors can assess how severe the prolapse is, but existing tools do not provide much information about what’s happening inside the tissue itself.
UCI Health, the clinical enterprise of the University of California, Irvine, is conducting a first-in-human, Phase I clinical trial using laser light to target localized but inoperable pancreatic tumors to help patients become cancer-free.
Adelaide University researchers have developed a new way to use mRNA technology to reprogram tumor-supporting immune cells and strengthen the body’s anticancer immune response.
Columbia University researchers have identified a way to help predict when people at high risk of developing Alzheimer’s are likely to develop their first symptoms, a finding that could help physicians decide when to prescribe preventive treatments currently in development.
IceCure Medical Ltd. announced that it has received approval, as a Class III medical device, from China’s National Medical Products Administration (“NMPA”) for its ProSense® system and associated cryoprobes.